Therapeutic uses of bactericidal/permeability increasing protein

Details Therapeutic uses of bactericidal/permeability increasing protein Therapeutic uses of bactericidal/permeability increasing protein

1995-03-31

1997-06-17

Patterson, Jr., Charles L.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 13, 514 14, 514 15, 514 21, 435 691, 530324, 530350, A61K 3800, C12P 2106, C07K 100, C07K 200

Patent

active

056397275

ABSTRACT:
The present invention provides therapeutic methods for treatment of conditions including the neutralization of the anti-coagulant activity of heparin, inhibition of angiogenesis, tumor and endothelial cell proliferation, and treatment of chronic inflammatory diseases by administration of bactericidal/permeability-increasing (BPI) protein products.

REFERENCES:
patent: 5086164 (1992-02-01), Maione et al.
patent: 5112946 (1992-05-01), Maione
patent: 5171739 (1992-12-01), Scott et al.
patent: 5357041 (1994-10-01), Roberts et al.
patent: 5491130 (1996-02-01), Roberts et al.
Dialog Abstract File 155 Accesion No. 92257868, Kaklamanis, 1992. Clin Rheumatol. 11(1):41-47.
Reclini et al. 1988. (Abstract: Dialog File 155 Accession No. 88326267) Biochem. J. 252(2):515-519.
Murav'ev, 1980. (Abstract: Biosis No.: 73034154) Ter Arkh 52(11):126-129.
Marra et al. Aug. 23, 1990. (Abstract; WPI Accession No.: 90-274947/36.
Azizkhan et al., "Mast Cell Heparin Stimulates Migration of Capillary Endothelial Cells In Vitro," J. Exp. Med., 152:931-944 (Oct. 1980).
Brahn, "Animal Modles of Rheumatoid Arthritis," Clin. Orthopaedics and Related Res., 265:42-53 (Apr. 1991).
Castellot et al., "Heparin Potentiation of 3T3-Adipocyte Stimulated Angiogenesis: Mechanism of Action on Endothelial Cells," J. Cell. Phys.127:328-329 (1986).
Cremer et al., "Collagen-Induced Arthritis In Rats," J. Immunol., 149(3):1045-1053 (Aug. 1, 1992).
Folkman et al., "Angiogenesis Inhibition and Tumor Regression Caused by Heparin or a Heparin Fragment in the Presence of Cortisone," Science, 221:719-725 (Aug. 19, 1983).
Gallagher, "Heparan Sulphates as Membrane Receptors for the Fibroblast Growth Factors," Eur. J. Clin. Chem. Clin. Biochem., 32(4):239-247 (1994).
Harris, "Rheumatoid Arthritis Pathology and Implications for Therapy," New Engl. J. Med., 322(18):1277-1289 (1990).
Ishihara et al., "A Cell Based Assay for Evaluating the Interaction of Heparin-like Molecules and Basic Fibroblast," Analytical Biochem., 202:310-315 (1992).
Kingsley and Sieper, "Current perspectives in reactive arthritis," Immunol. Today, 14(8):387-391 (1993).
Leff, "NCI Seeks Company To Co-Develop Anti-Cancer Drugs That Block Tumor Angiogenesis," BioWorld Today, 7(125):1&5 (Jun. 26, 1996).
Lichtman et al., "Reactivation of Arthritis Induced by Small Bowel Bacterial Overgrowth in Rats: Role of Cytokines, Bacteria, and Bacterial Polymers," Infect. Immun., 63(6):2295-2301 (Jun. 1995).
Mitchell and Wilks, "Inhibitors of Angiogenesis", Chapter 15, pp. 139-148 in Annual Reports in Medical Chemistry, vol. 27, Academic Press, Inc. (1992).
Murav'ev et al., "Effect of Heparin Therapy on Clinico-Laboratory Indicators In Rheumatoid Arthritis Patients," Ter. Arkh., 52(11);126-129 (1980)--English translation.
Phadke et al., "Evaluation of the Effects of Various Anti-Arthritic Drugs on Type II Collagen-Induced Mouse Arthritis Model," Immunopharmacology, 10:51-60 (1985).
Stuart et al., "Nature and the Specificity of the Immune Response to Collagen in Type II Collagen-induced Arthritis in Mice", J. Clin. Invest., 69:673-683 (Mar. 1982).
Vogel et al., "Modulation of Endothelial Cell Proliferation, Adhesion, and Motility by Recombinant Heparin-Binding Domain and Synthetic Peptides From the Type I Repeats of Thrombospondin", J. Cellular Biochem., 53:74-84 (1993).
Weiss et al., "Determinants of the Action of Phospholipases A on the Envelope Phospholipids of Escherichia coli," J. Biol. Chem., 254(21):11010-11014 (1979).
Wooley, "Animal models of rheumatoid arthritis," Curr. Opp. Rheumat., 3:407-420 (1991).
Yayon et al., "Cell Surface, Heparin-Like Molecules are Required for Binding of Basic Fibroblast Growth Factor to Its High Affinity Receptor", Cell, 64:841-848 (Feb. 22, 1991).
Charles, et al., J. Biol. Chem., "The Three-dimensional Structure of Bovine Platelet Factor 4 at 3.0 A Resolution," 264(4):29092-2099 (Feb. 5, 1989).
Cook, et al., Circulation, "Platelet Factor 4 Efficiently Reverses Heparin Anticoagulation in the Rat Without Adverse Effects of Heparin-Protamine Complexes," 85(3): 1102-1109 (Mar., 1992).
Elsbach, et al., Inflammation: Basic Principles and Correlates, "Oxygen-Independent Antimicrobial Systems of Phagocytes," 2nd. Ed., Review Press, Ltd. Chapter 30, pp. 603-636 (1992).
Elsbach, et al., J. Biol. Chem., "Separation and Purification of a Potent Bactericidal/Permeability-increasing Protein and a closely Associated Phospholipase A.sub.2 from Rabbit Polymorphonuclear Leukocytes," 254(21): 11000-11009 (Nov. 10, 1979).
Folkman, et al., Inflammation: Basic Principles and Correlates, "Abiogenesis and Inflammation," 2nd, Ed., Review Press, Ltd., Chapter 40, pp. 821-839 (1992).
Gammon, et al., J. Exp. Med., "T Cell Determinant Structure: Cores and Determinant Envelopes in Three Major Mouse Hsitocompatability Complex Halotypes," 173:609-617 (Mar., 1991).
Garcia, et al., BioWorld Today, "Repligen IND for Platelet Factor," p. 5 (Jan. 11, 1983).
Gazzano-Santoro, et al., Infect. Immunol., "High Affinity Binding of the Bactericidal/Permeability Increasing Protein and a Recombinant Amino-Terminal Fragment to the Lipid A Region of Lipopolysacchride," 60(11): 4754-4761 (Nov., 1992).
Gray, et al., J. Biol. Chem., "Cloning of the cDNA of a Human Neutrophil Bactericidal Protein," 264(16): 9505-9509 (Jun. 5, 1989).
Heyderman, et al., Thrombosis Res., "Reduction of the Anticoagulant Activity of Glycosaminoglycans on the Surface of the Vascular Endothelium by Endotoxin and Neutrophils: Evaluation by an Amidolytic Assay," 67: 677-685 (Apr. 28, 1992).
Hiti-Harper, et al., Science, "Platelet Factor 4: An Inhibitor of Collagenase," 199: 991-992 (Mar. 3, 1978).
Maeji, et al. J. Immunol. Methods, "Multi-pin Peptide Strategy for T cell determinant analysis," 134: 23-33 (1990).
Maione, et al., Cancer Res., "Inhibition of Tumor Growth in Mice by an Analogue of Platelet Factor 4 That Lacks Affinity for Heparin and Retains Potent Angiostatic Activity," 51:2077-2083 (Apr. 15, 1991).
Maione, et al., CAS BioTech Updates--Antibody Conjugates, pp. 1, 1334, 117:226303x (Issue Jun. 16, 1992).
Marra, et al., J. Immunol., "The Role of Bactericidal/Permeability-Increasing Protein as a Natural Inhibitor of Bacterial Endotoxin," 148:532-537 (Jan. 15, 1992).
Weiss, et al., J. Clin. Invest., "Partial Characterization and Purification of a Rabbit Granulocyte Factor That Increases Permeability of Escheria coli," 55:33-42 (1975).
Yayon, et al., Cell, "Cell Surface, Heparin-like Molecules Are Required for Binding of Basic Fibroplast Growth to its High Affinity Recptor," 64:641-648 (Feb. 22, 1991).
Yong, et al., Microbial Pathogenesis, "An experimental mouse model of Yersinia-induced reactive arthritis," 4:305-310 (1988).
Merrifield, et al., Anal. Chem., "Instrument for Automated Synthesis of Peptides," 38(13): 1905-1914 (Dec., 1966).
Merrifield, et al., J. Am. Chem. Soc., "Solid Phase Peptide Synthesis," 85: 2149-2154 (Jul. 20, 1963).
Miles, et al., VII International Conference on Aids, Florence, Italy, "Recombinant Platelet Factor 4 (rPF4) and a Non-heparin Binding Derivative Inhibit Aids-Kaposi Sarcoma Derived Cell Lines," Paper 41(8), W.A. 1066 p. 108 (Jun. 16-21, 1991).
Ooi, et al., J. Exp. Med., "Endotoxin-neutralizing Properties of the 25kD N-Terminal Fragment and a New Isolated 30 kD C-Terminal Fragment of the 55-60 kD Bactericidal/Permability-increasing Protein of Human Neutrophils," 174: 649 (1991).
Peacock, et al., J. Exp. Med., "Angiobiogenesis Inhibition Suppresses Collagen Arthritis," 175: 1135-1138 (Apr., 1992).
Repligen Corporation, Research in Review, Spring 1992.
Stuart, et al., J. Clin. Invest., "Nature and the Specificity of the Immune Response to Collagen in Type II Collagen-induced Arthritis in Mice," 69: 673-683 (Mar., 1982).
Takayama, et al., Infect. and Immun., "Absence of Lipopoylsaccharide in the Lyme Disease Spirochete," 55(9): 2311-2312 (Sep., 1987).
Taylor, et al., Nature, "Protamine is an inhibitor of angiogenesis," 297:307-312 (May 27, 1982).
Tontsch, et al., Microvascular Res., "Isolation, Characterization, and Long-Term Cultivation of Porcine and Murine Cerebral Capillary End

Affiliated with

Also associated with

Rating

Therapeutic uses of bactericidal/permeability increasing protein does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic uses of bactericidal/permeability increasing protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic uses of bactericidal/permeability increasing protein will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2157801